Review
Open access
Oct 2026
Immune Checkpoint Inhibitors: Sculpting the Landscape of Endometrial Cancer Treatment
Background: Outcomes for advanced or recurrent endometrial cancer (EC) remain poor, with historically limited systemic options beyond platinum-based chemotherapy. EC is uniquely immunotherapy-amenable among solid tumors: it harbors the highest prevalence of mismatch repair deficiency (dMMR) and microsatellite instabili...
Allan Huang, L. Mulugeta-Gordon, D. Nasioudis et al.
· Cancers · 0 citations